Table 2.

In vivo efficacy of HuNAbs determined in animal models

Antibody	Dosage (mg/kg)	Animal model	Experiments	Efficacy	Reference
REGN-COV2	50, 5, 0.5	Syrian hamster	Prophylactic (−2 day)	Alter the course of infection	Baum et al. (2020) [75]
			Treatment (1 dpi∗)	Alter the course of infection
	50, 0.3	Rhesus macaque	Prophylactic (−3 day)	50 mg/kg could minimize virus replication, but 0.3 mg/kg could not
	150, 25		Treatment (1 dpi)	Accelerate viral clearance at both dosage
BD-368-2	20	hACE2 transgenic mice	Prophylactic (−1 day)	Completely inhibit infection in lung	Cao et al. (2020) [19]
			Therapeutic (2h after infection)	3–4 logs decrease in virus copies in lung
H014	50	hACE2-humanized mice	Prophylactic (−12 hour) plus therapeutic (4 hours after infection)	1–2 logs decrease in virus copies in lung	Lv et al. (2020) [74]
			Therapeutic (4 hours after infection)	0.5–1 log decrease in virus copies in lung
2-15	1.5	Syrian hamster	Prophylactic (−1 day)	4 logs or more decrease in virus copies in lung	Liu et al. (2020) [26]
1B07	10	AdV-hACE2- transducedBALB/c mice	Prophylactic (−1 day)	About 1 log decrease in virus copies in lung	Hassan et al. (2020) [20]
CB6	50	Rhesus macaque	Prophylactic (−1 day)	4–5 logs decrease in virus copies in lung	Shi et al., (2020) [52]
			Treatment (1 dpi and 3 dpi)	3–4 logs decrease in virus copies in lung
COV2-2196/2130	0.2mg/mice	AdV-hACE2- transducedBALB/c mice	Prophylactic (−1day)	About 1 log decrease in virus copies in lung	Zost et al. (2020) [76]
	50		Prophylactic (−3 day)	Completely inhibit infection in lung
		Rhesus macaque
CC12.1/C12.23	16.5, 4.2, 0.9, 0.2, 0.06	Syrian hamster	Prophylactic (−1day)	16.5, 4.2, 0.9 mg/kg could minimize virus replication, 0.2, but 0.06 mg/kg could not	Rogers et al. (2020) [73]

∗dpi: day post infection.